e-learning
resources
Vienna 2012
Wednesday, 05.09.2012
The smoking gun in COPD biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Different pathology of pulmonary arterioles in centrilobular and panlobular emphysema
G. Turato, A. Ballarin, C. Scattolin, S. Baraldo, E. Bazzan, E. Mutti, B. Molena, M. Damin, E. Balestro, P. Maestrelli, M. Saetta, M. Cosio (Padova, Italy; Montreal, Canada)
Source:
Annual Congress 2012 - The smoking gun in COPD biology
Session:
The smoking gun in COPD biology
Session type:
Poster Discussion
Number:
4591
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Turato, A. Ballarin, C. Scattolin, S. Baraldo, E. Bazzan, E. Mutti, B. Molena, M. Damin, E. Balestro, P. Maestrelli, M. Saetta, M. Cosio (Padova, Italy; Montreal, Canada). Different pathology of pulmonary arterioles in centrilobular and panlobular emphysema. Eur Respir J 2012; 40: Suppl. 56, 4591
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Diffuse pulmonary fibrosis and pulmonary emphysema associated with paradoxically normal spirometry
Source: Eur Respir J 2006; 28: Suppl. 50, 100s
Year: 2006
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
Ectopic subpleural fat deposition in idiopathic pulmonary fibrosis correlates with radiographic extension of fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Combined pulmonary emphysema and fibrosis in connective tissue disease
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2014 – ILDs 1
Year: 2014
Clinical features of combined pulmonary fibrosis and emphysema
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Markers of fibrosis and tissue destruction in usual interstitial pneumonia associated with pulmonary emphysema
Source: Eur Respir J 2007; 30: Suppl. 51, 489s
Year: 2007
Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema
Source: ERJ Open Res, 7 (3) 00316-2021; 10.1183/23120541.00316-2021
Year: 2021
Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011
Irreversible pneumosclerosis in idiopathic lung fibrosis at stage of honeycombing
Source: Eur Respir J 2005; 26: Suppl. 49, 550s
Year: 2005
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Diffuse parenchymal lung disease
Source: Eur Respir Rev, 26 (144) 170004; 10.1183/16000617.0004-2017
Year: 2017
Diffuse parenchymal lung disease
Source: International Congress 2016 – Clinical year in review
Year: 2016
Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis?
Source: International Congress 2014 – ILDs 1
Year: 2014
US of subpleural lung lesions
Source: Annual Congress 2008 - Radiology Grand Round - an interactive session
Year: 2008
Changes in the small airways in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Diffuse alveolar hemorrhage and pulmonary fibrosis in MPO-ANCA-associated vasculitides
Source: Eur Respir J 2005; 26: Suppl. 49, 267s
Year: 2005
Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept